A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease

Scott, Robert A., Freitag, Daniel F., Li, Li, Chu, Audrey Y., Surendran, Praveen, Young, Robin, Grarup, Niels, Stancakova, Alena, Chen, Yuning, Varga, Tibor V., Yaghootkar, Haniel, Luan, Jian'an, Zhao, Jing Hua, Willems, Sara M., Wessel, Jennifer, Wang, Shuai, Maruthur, Nisa, Michailidou, Kyriaki, Pirie, Ailith, van der Lee, Sven J., Gillson, Christopher, Al Olama, Ali Amin, Amouyel, Philippe, Arriola, Larraitz, Arveiler, Dominiquw, Aviles-Olmos, Iclar, Balkau, Beverley, Barricarte, Aurelio, Barroso, Ines, Garcia, Sara Benlloch, Bis, Joshua C., Blankenberg, Stefan, Boehnke, Michael, Boeing, Heiner, Boerwinkle, Eric, Borecki, Ingrid B., Bork-Jensen, Jette, Bowden, Sarah, Caldas, Carlos, Caslake, Muriel, Cupples, L. Adrienne, Cruchaga, C., Czajkowski, J., den Hoed, M., Dunn, J. A., Earl, H. M., Ehret, G. B., Ferrannini, E., Ferrieres, J., Foltynie, T., Ford, I., Forouhi, N. G., Gianfagna, F., Gonzalez, C., Grioni, S., Hiller, L., Jansson, J.-H., Jorgensen, M. E., Jukema, J. W., Kaaks, R., Kee, F., Kerrison, N. D., Key, T. J., Kontto, J., Kote-Jarai, Z., Kraja, A. T., Kuulasmaa, K., Kuusisto, J., Linneberg, A., Liu, C., Marenne, G., Mohlke, K. L., Morris, A. P., Muir, K., Muller-Nurasyid, M., Munroe, P. B., Navarro, C., Nielsen, S. F., Nilsson, P. M., Nordestgaard, B. G., Packard, C. J., Palli, D., Panico, S., Peloso, G. M., Perola, M., Peters, A., Poole, C. J., Quiros, J. R., Rolandsson, O., Sacerdote, C., Salomaa, V., Sanchez, M.-J., Sattar, N., Sharp, S. J., Sims, Rebecca ORCID: https://orcid.org/0000-0002-3885-1199, Slimani, N., Smith, J. A., Thompson, D. J., Trompet, S., Tumino, R., van der A, D. L., van der Schouw, Y. T., Virtamo, J., Walker, M., Walter, K., Abraham, J. E., Amundadottir, L. T., Aponte, J. L., Butterworth, A. S., Dupuis, J., Easton, D. F., Eeles, R. A., Erdmann, J., Franks, P. W., Frayling, T. M., Hansen, T., Howson, J. M. M., Jorgensen, T., Kooner, J., Laakso, M., Langenberg, C., McCarthy, M. I., Pankow, J. S., Pedersen, O., Riboli, E., Rotter, J. I., Saleheen, D., Samani, N. J., Schunkert, H., Vollenweider, P., O'Rahilly, S., Deloukas, P., Danesh, J., Goodarzi, M. O., Kathiresan, S., Meigs, J. B., Ehm, M. G., Wareham, N. J. and Waterworth, D. M. 2016. A genomic approach to therapeutic target validation identifies a glucose-lowering GLP1R variant protective for coronary heart disease. Science Translational Medicine 8 (341) , 341ra76. 10.1126/scitranslmed.aad3744

Preview

PDF - Accepted Post-Print Version Download (1MB) | Preview

Abstract

Regulatory authorities have indicated that new drugs to treat type 2 diabetes (T2D) should not be associated with an unacceptable increase in cardiovascular risk. Human genetics may be able to guide development of antidiabetic therapies by predicting cardiovascular and other health endpoints. We therefore investigated the association of variants in six genes that encode drug targets for obesity or T2D with a range of metabolic traits in up to 11,806 individuals by targeted exome sequencing and follow-up in 39,979 individuals by targeted genotyping, with additional in silico follow-up in consortia. We used these data to first compare associations of variants in genes encoding drug targets with the effects of pharmacological manipulation of those targets in clinical trials. We then tested the association of those variants with disease outcomes, including coronary heart disease, to predict cardiovascular safety of these agents. A low-frequency missense variant (Ala316Thr; rs10305492) in the gene encoding glucagon-like peptide-1 receptor (GLP1R), the target of GLP1R agonists, was associated with lower fasting glucose and T2D risk, consistent with GLP1R agonist therapies. The minor allele was also associated with protection against heart disease, thus providing evidence that GLP1R agonists are not likely to be associated with an unacceptable increase in cardiovascular risk. Our results provide an encouraging signal that these agents may be associated with benefit, a question currently being addressed in randomized controlled trials. Genetic variants associated with metabolic traits and multiple disease outcomes can be used to validate therapeutic targets at an early stage in the drug development process.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG)
Subjects:	R Medicine > R Medicine (General)
Publisher:	American Association for the Advancement of Science
ISSN:	1946-6234
Date of First Compliant Deposit:	2 January 2018
Date of Acceptance:	10 May 2016
Last Modified:	24 Nov 2024 18:15
URI:	https://orca.cardiff.ac.uk/id/eprint/97720

Citation Data

Cited 75 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item